297 related articles for article (PubMed ID: 18342171)
21. [PSA/volume ratio in prostatic disease in the elderly].
Bo M; Ventura M; Massaia M; Fabris F
Recenti Prog Med; 2001 Oct; 92(10):594-8. PubMed ID: 11695303
[TBL] [Abstract][Full Text] [Related]
22. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
24. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia.
Stone NN; Clejan SJ
J Androl; 1991; 12(6):376-80. PubMed ID: 1722793
[TBL] [Abstract][Full Text] [Related]
25. Changes in prostate-specific antigen levels and prostate volume in octogenarian men: community-based study.
Chung JS; Byun SS; Han BK; Jeong SJ; Hong SK; Lee SE
Urology; 2009 Jun; 73(6):1270-3. PubMed ID: 19371943
[TBL] [Abstract][Full Text] [Related]
26. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
27. Intra-individual variation of serum prostate specific antigen levels in men with benign prostate biopsies.
Boddy JL; Dev S; Pike DJ; Malone PR
BJU Int; 2004 Apr; 93(6):735-8. PubMed ID: 15049982
[TBL] [Abstract][Full Text] [Related]
28. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
[TBL] [Abstract][Full Text] [Related]
29. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between serum PSA and prostate volume in benign hyperplasia].
Ojea Calvo A; Rodrigo AA; Verez Vivero MM; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; Nogueira March JL
Actas Urol Esp; 1994 Mar; 18(3):178-80. PubMed ID: 7518640
[TBL] [Abstract][Full Text] [Related]
31. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
Chakrabarti S; Raha K; Bhunia CL; Bhattachary DK
J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
[TBL] [Abstract][Full Text] [Related]
32. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
33. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
Bhuiyan AK; Kibria SA; Subhan SS
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
[TBL] [Abstract][Full Text] [Related]
34. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
35. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
Hall MC; Roehrborn CG; McConnell JD
Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
[TBL] [Abstract][Full Text] [Related]
36. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia.
Batislam E; Arik AI; Karakoc A; Uygur MC; Germiyanoğlu RC; Erol D
Urology; 1997 Jan; 49(1):50-4. PubMed ID: 9000185
[TBL] [Abstract][Full Text] [Related]
37. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia.
Hochberg DA; Armenakas NA; Fracchia JA
Prostate; 2000 Dec; 45(4):315-9. PubMed ID: 11102956
[TBL] [Abstract][Full Text] [Related]
38. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
39. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
40. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
